Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

A number of other equities research analysts also recently commented on SUPN. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals currently has an average rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $48.05 on Friday. The company has a 50 day moving average price of $47.18 and a two-hundred day moving average price of $49.50. The stock has a market capitalization of $2.79 billion, a P/E ratio of -94.22, a PEG ratio of 1.03 and a beta of 0.54. Supernus Pharmaceuticals has a one year low of $31.35 and a one year high of $59.68.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of large investors have recently bought and sold shares of SUPN. Empowered Funds LLC acquired a new position in shares of Supernus Pharmaceuticals in the 1st quarter valued at $264,000. Bank of America Corp DE raised its position in shares of Supernus Pharmaceuticals by 37.2% in the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after buying an additional 193,479 shares during the period. California State Teachers Retirement System raised its position in shares of Supernus Pharmaceuticals by 26.9% in the 1st quarter. California State Teachers Retirement System now owns 67,686 shares of the specialty pharmaceutical company’s stock worth $3,499,000 after buying an additional 14,347 shares during the period. Ashford Capital Management Inc. boosted its holdings in Supernus Pharmaceuticals by 5.4% in the first quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock valued at $33,360,000 after acquiring an additional 32,843 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its holdings in Supernus Pharmaceuticals by 7.5% in the first quarter. Quantinno Capital Management LP now owns 26,209 shares of the specialty pharmaceutical company’s stock valued at $1,355,000 after acquiring an additional 1,818 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.